Latest articles
Calm, cited readings of material exchange filings. Cited, not tips.
Sort:Newest
Sector:Healthcare
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 5 Aug · 2 min
Aurobindo Pharma consolidates Lannett for the first time in Q1 FY27
The quarter ended June 30, 2026 is the first to include newly acquired US business Lannett Company LLC, which the company says makes results non-comparable to prior periods.
AUROPHARMA · Aurobindo Pharma Limited · BSE · Filed 5 Aug · 1 min
Aurobindo Pharma Q1 FY27 revenue up 16.3%, led by Europe and Growth Markets
Aurobindo reported consolidated Q1 FY27 revenue of ₹9,150 crore and net profit of ₹1,032 crore, with growth across formulations and API.
SUNPHARMA · Sun Pharmaceutical Industries Limited · NSE · Filed 31 Jul · 2 min
Sun Pharma Q1 FY27: sales up 10.1%, Organon deal cleared by target's shareholders
Consolidated sales and net profit both rose year-on-year, even as US generics slipped and the pending Organon acquisition began flowing costs through exceptional items.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 21 Jul · 1 min
Aurobindo's CuraTeQ Biologics clears ANVISA inspection for Hyderabad biosimilars plant
Brazil's health regulator approved the wholly owned subsidiary's Hyderabad facility after a GMP inspection, adding Brazilian and Latin American markets to those the plant can supply.
AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 30 Jun · 1 min
Aurobindo completes acquisition of US generics firm Lannett
Aurobindo Pharma USA has closed its purchase of Lannett Company, which will now operate as a wholly owned subsidiary after US regulatory clearance.